LGND
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Ligand Pharmaceuticals Incorporated
- Nom
- Ligand Pharmaceuticals Incorporated
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $6.1B
- Employés
- 47
- PDG
- Todd C. Davis
- Site web
- https://www.ligand.com
- Marché
- ABBVAMGNBCRXBMYEXELGMAB
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 8 338 titres (~2 432 062,08 $ US)
- Insiders
- Zimmermann MartineHaas Jason
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$11,913,877
Avg sell (VWAP, 90d window) $291.97 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$9,481,815 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Reardon Andrew | Sell · S · 10b5-1 | 17 | $307.74 | $5,232 | Form 4 |
| 2026-09-10 | Zimmermann Martine | Sell · S | 1,200 | $285.00 | $342,000 | Form 4 |
| 2026-09-03 | Reardon Andrew | Sell · S · 10b5-1 | 400 | $288.98 | $115,592 | Form 4 |
| 2026-08-12 | Espinoza Octavio | Sell · S · 10b5-1 | 31,641 | $292.06 | $9,241,229 | Form 4 |
| 2026-08-12 | Haas Jason | Sell · S | 7,138 | $292.81 | $2,090,062 | Form 4 |
| 2026-08-03 | Reardon Andrew | Sell · S · 10b5-1 | 409 | $292.82 | $119,763 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-29 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-15 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-05 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-22 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-04-03 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
LGND presents a compelling financial profile with top-tier liquidity (95) and strong fundamental momentum (85), underpinned by exceptional margins and a robust balance sheet.
The first sentence of the analysis written for LGND on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 4 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 22.23 · operating margin 18%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.5% | 93.4% | 73.3% | 73.1% | 74.3% | |
| Ebit Margin | 59.3% | 3.3% | 49.0% | 19.3% | 38.0% | |
| Ebitda Margin | 71.9% | 24.4% | 76.8% | 41.4% | 59.1% | |
| Operating Profit Margin | 17.6% | -13.5% | 9.1% | 1.5% | 43.0% | |
| Pretax Profit Margin | 59.3% | 1.5% | 48.5% | 18.4% | 29.9% | |
| Continuous Operations Profit Margin | 46.4% | -2.4% | 41.0% | -2.7% | 31.6% | |
| Net Profit Margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | |
| Bottom Line Profit Margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | |
| Current Ratio | 22.225 | 8.934 | 14.148 | 2.668 | 11.154 | |
| Quick Ratio | 21.982 | 8.554 | 12.720 | 2.533 | 10.499 | |
| Solvency Ratio | 0.291 | 0.280 | 1.027 | 0.061 | 0.227 | |
| Cash Ratio | 4.671 | 1.948 | 1.368 | 0.455 | 0.469 | |
| Price To Earnings Ratio | 29.359 | -487.045 | 23.649 | -33.737 | 27.850 | |
| Price To Earnings Growth Ratio | -0.010 | 4.540 | -0.094 | 0.215 | -0.014 | |
| Forward Price To Earnings Growth Ratio | -0.010 | 4.540 | -0.094 | 0.215 | -0.014 | |
| Price To Earnings Diluted Ratio | 30.843 | -487.045 | 24.293 | -33.737 | 28.850 | |
| Price To Earnings Diluted Growth Ratio | -0.011 | 4.531 | -0.098 | 0.212 | -0.015 | |
| Price To Book Ratio | 3.594 | 2.360 | 1.763 | 1.886 | 1.951 | |
| Price To Sales Ratio | 13.638 | 11.726 | 9.408 | 5.742 | 6.634 | |
| Price To Free Cash Flow Ratio | 74.759 | 25.318 | -289.191 | 9.396 | 22.880 | |
| Price To Operating Cash Flow Ratio | 74.074 | 20.194 | 24.919 | 8.174 | 20.336 | |
| Debt To Assets Ratio | 0.289 | 0.008 | 0.008 | 0.115 | 0.250 | |
| Debt To Equity Ratio | 0.444 | 0.009 | 0.009 | 0.147 | 0.395 | |
| Debt To Capital Ratio | 0.307 | 0.008 | 0.009 | 0.128 | 0.283 | |
| Long Term Debt To Capital Ratio | 0.305 | 0.000 | 0.000 | 0.000 | 0.281 | |
| Financial Leverage Ratio | 1.534 | 1.134 | 1.123 | 1.276 | 1.580 | |
| Working Capital Turnover Ratio | 0.492 | 0.649 | 0.681 | 0.668 | 0.587 | |
| Operating Cash Flow Ratio | 1.318 | 2.615 | 2.954 | 1.395 | 1.891 | |
| Operating Cash Flow Sales Ratio | 0.184 | 0.581 | 0.378 | 0.702 | 0.326 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.991 | 0.798 | -0.086 | 0.870 | 0.889 | |
| Debt Service Coverage Ratio | 33.558 | 11.276 | 138.713 | 0.509 | 7.489 | |
| Interest Coverage Ratio | 10.010 | -7.444 | 18.204 | 1.688 | 5.293 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 1.797 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.109 | 13.659 | 8.042 | 1.571 | 0.243 | |
| Capital Expenditure Coverage Ratio | 109.201 | 4.941 | 0.921 | 7.691 | 8.994 | |
| Dividend Paid And Capex Coverage Ratio | 109.201 | 4.941 | 0.921 | 7.691 | 8.994 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.405 | 46.442 | 12.085 | 14.402 | 13.359 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.5% | ▲4.2% | ▲15.2% |
| Ebit Margin | 59.3% | ▲56.0% | ▲25.5% |
| Ebitda Margin | 71.9% | ▲47.5% | ▲17.2% |
| Operating Profit Margin | 17.6% | ▲31.1% | ▲6.1% |
| Pretax Profit Margin | 59.3% | ▲57.8% | ▲27.8% |
| Continuous Operations Profit Margin | 46.4% | ▲48.8% | ▲23.6% |
| Net Profit Margin | 46.4% | ▲48.8% | ▲28.3% |
| Bottom Line Profit Margin | 46.4% | ▲48.8% | ▲28.3% |
| Current Ratio | 22.225 | ▲13.291 | ▲10.399 |
| Quick Ratio | 21.982 | ▲13.428 | ▲10.724 |
| Solvency Ratio | 0.291 | ▲0.011 | ▼-0.086 |
| Cash Ratio | 4.671 | ▲2.723 | ▲2.889 |
| Price To Earnings Ratio | 29.359 | ▲516.404 | ▲117.344 |
| Price To Earnings Growth Ratio | -0.010 | ▼-4.549 | ▼-0.937 |
| Forward Price To Earnings Growth Ratio | -0.010 | ▼-4.549 | ▼-0.937 |
| Price To Earnings Diluted Ratio | 30.843 | ▲517.889 | ▲118.203 |
| Price To Earnings Diluted Growth Ratio | -0.011 | ▼-4.542 | ▼-0.935 |
| Price To Book Ratio | 3.594 | ▲1.234 | ▲1.284 |
| Price To Sales Ratio | 13.638 | ▲1.912 | ▲4.209 |
| Price To Free Cash Flow Ratio | 74.759 | ▲49.441 | ▲106.127 |
| Price To Operating Cash Flow Ratio | 74.074 | ▲53.880 | ▲44.535 |
| Debt To Assets Ratio | 0.289 | ▲0.282 | ▲0.155 |
| Debt To Equity Ratio | 0.444 | ▲0.435 | ▲0.243 |
| Debt To Capital Ratio | 0.307 | ▲0.299 | ▲0.160 |
| Long Term Debt To Capital Ratio | 0.305 | ▲0.305 | ▲0.188 |
| Financial Leverage Ratio | 1.534 | ▲0.400 | ▲0.205 |
| Working Capital Turnover Ratio | 0.492 | ▼-0.157 | ▼-0.123 |
| Operating Cash Flow Ratio | 1.318 | ▼-1.297 | ▼-0.717 |
| Operating Cash Flow Sales Ratio | 0.184 | ▼-0.397 | ▼-0.250 |
| Free Cash Flow Operating Cash Flow Ratio | 0.991 | ▲0.193 | ▲0.299 |
| Debt Service Coverage Ratio | 33.558 | ▲22.283 | ▼-4.751 |
| Interest Coverage Ratio | 10.010 | ▲17.454 | ▲4.460 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-0.359 |
| Operating Cash Flow Coverage Ratio | 0.109 | ▼-13.550 | ▼-4.615 |
| Capital Expenditure Coverage Ratio | 109.201 | ▲104.260 | ▲82.852 |
| Dividend Paid And Capex Coverage Ratio | 109.201 | ▲104.260 | ▲82.852 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.405 | ▼-26.037 | ▼-0.934 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.66B | $1.96B | $1.24B | $1.13B | $1.60B | |
| Enterprise value | $3.93B | $1.89B | $1.22B | $1.17B | $1.91B | |
| EV / Sales | 14.67x | 11.34x | 9.28x | 5.96x | 7.90x | |
| EV / Op. cash flow | 79.68x | 19.52x | 24.58x | 8.48x | 24.20x | |
| EV / Free cash flow | 80.41x | 24.48x | -285.26x | 9.75x | 27.23x | |
| EV / EBITDA | 20.41x | 46.44x | 12.09x | 14.40x | 13.36x | |
| Net debt / EBITDA | 1.44x | -1.60x | -0.17x | 0.53x | 2.13x | |
| Current ratio | 22.23x | 8.93x | 14.15x | 2.67x | 11.15x | |
| Income quality | 0.40x | -24.07x | 0.95x | -4.13x | 1.38x | |
| Graham number | $87 | — | $52 | — | $62 | |
| Graham net-net | $12 | $10 | $7 | $5 | -$3 | |
| Tax burden | 78.3% | -160.1% | 81.9% | -92.6% | 79.1% | |
| Interest burden | 100.0% | 45.3% | 99.0% | 95.2% | 78.6% | |
| Working capital | $794.8M | $294.4M | $220.6M | $164.8M | $423.1M | |
| Invested capital | $1.33B | $691.2M | $648.7M | $650.6M | $948.2M | |
| Return on assets | 8.0% | -0.4% | 6.6% | -4.4% | 4.4% | |
| Operating ROA | 3.8% | -2.6% | 1.5% | 0.3% | 7.8% | |
| Return on tangible assets | 12.0% | -0.7% | 13.6% | -11.0% | 7.1% | |
| Return on equity | 12.2% | -0.5% | 7.4% | -5.6% | 7.0% | |
| Return on invested capital | 2.4% | 4.0% | 1.3% | -0.1% | 8.3% | |
| Return on capital employed | 3.1% | -2.5% | 1.6% | 0.5% | 8.3% | |
| Earnings yield | 3.4% | -0.2% | 4.2% | -3.0% | 3.6% | |
| Free cash flow yield | 1.3% | 3.9% | -0.3% | 10.6% | 4.4% | |
| Capex / Op. cash flow | 0.9% | 20.2% | 108.6% | 13.0% | 11.1% | |
| Capex / Depreciation | 1.3% | 55.7% | 147.4% | 34.9% | 17.2% | |
| Capex / Sales | 0.2% | 11.8% | 41.0% | 9.1% | 3.6% | |
| SG&A / Sales | 34.5% | 47.1% | 40.2% | 35.7% | 19.4% | |
| R&D / Sales | 30.3% | 12.8% | 18.7% | 18.4% | 13.3% | |
| Stock comp / Sales | 0.0% | 24.6% | 19.6% | 30.7% | 16.1% | |
| Intangibles / Total assets | 33.6% | 39.5% | 51.2% | 60.1% | 38.0% | |
| Days sales outstanding | 83d | 93d | 109d | 65d | 138d | |
| Days payables outstanding | 179d | 172d | 25d | 37d | 49d | |
| Operating cycle | 589d | 558d | 359d | 157d | 299d | |
| Cash conversion cycle | 409d | 385d | 334d | 120d | 250d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-15 Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND) Omeros (NASDAQ: OMER - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Profitability This table compares Omeros and Ligand Pharmaceuticals'' net
- 2026-08-26 Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
- 2026-08-26 Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.
- 2026-08-16 Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,358 shares of the biotechnology company''s stock after purchasing an additional 1,900 shares during the quarter.
- 2026-08-06 Ligand Pharmaceuticals Q2 Earnings Call Highlights Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
- 2026-08-06 Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
- 2026-08-05 Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 27.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,564 shares of the biotechnology company''s stock after selling 5,472 shares during the period.
- 2026-07-28 Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 207,565 shares of the biotechnology company''s stock after selling 6,213 shares during the quarter. Ligand Pharmaceuticals makes
- 2026-07-23 Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.
- 2026-07-21 Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.